News

CHIANG MAI, THAILAND – The 2016 IASLC Asia Pacific Lung Cancer Conference (APLCC), held May 13-15, is organized under the aegis of International Association for the Study of Lung Cancer (IASLC), Thai Society of Clinical Oncology (TSCO), Chiang Mai Lung Cancer Group, Faculty of Medicine at the Chiang Mai University (CMU) and the local organizing committee of APLCC 2016.

CHIANG MAI, THAILAND – The 2016 IASLC Asia Pacific Lung Cancer Conference (APLCC), held May 13-15, is organized under the aegis of International Association for the Study of Lung Cancer (IASLC), Thai Society of Clinical Oncology (TSCO), Chiang Mai Lung Cancer Group, Faculty of Medicine at the Chiang Mai University (CMU) and the local organizing committee of APLCC 2016.

DENVER – Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, a small-molecule tyrosine kinase inhibitor.

CHIANG MAI, THAILAND – The biennial Asia Pacific Lung Cancer Conference (APLCC 2016), organized by the International Association for the Study of Lung Cancer (IASLC), will be held in Chiang Mai, Thailand from 13-15 May 2016. Lung cancer experts from several countries in the Asian-Pacific region with a wide range of expertise spanning prevention, treatment, research, and care and support fields will participate and be joined by noted lung cancer experts from around the world.

DENVER – The International Association for the Study of Lung Cancer (IASLC) applauds the U.S. FDA’s decision to extend its regulation of tobacco products to e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among other products. This action by the FDA puts these products more in alignment with the Family Smoking Prevention and Tobacco Control Act and is a vast step forward for public health.

DENVER –A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in NSCLC clinical trials.

Pages